Latanox (Latanoprost)

Latanoprost binds to prostaglandin F (FP) receptors in the eye’s ciliary body, triggering remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced outflow lowers intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension.

The dosing regimen for Latanox is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Typically, a single drop is instilled in the affected eye(s) once daily in the evening, but exact instructions must come from a qualified eye‑care professional.

Safety data for latanoprost in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician after a thorough risk‑benefit assessment.

To order Latanox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details, and any necessary import documentation.

Latanox (latanoprost) belongs to the prostaglandin analog class, which is often preferred as first‑line therapy because of its once‑daily dosing and strong intra‑ocular pressure‑lowering effect. Compared with beta‑blockers or carbonic anhydrase inhibitors, prostaglandin analogs generally provide greater pressure reduction with a convenient dosing schedule.

Latanox should be stored below 25 °C, in its original bottle, protected from light and moisture. Keep the container tightly closed when not in use. Do not freeze the solution, and discard any product that appears discolored or contains particles.

Latanox is applied as a single drop to the conjunctival sac of the affected eye(s) once daily, preferably in the evening. The patient should wash hands before use, avoid touching the tip of the bottle to the eye or any surface, and wait a few minutes before applying other eye medications.

Serious risks, though rare, include uveitis, macular edema, and severe allergic reactions that may affect vision. Patients should promptly report any sudden loss of vision, eye pain, redness, or swelling. Regular monitoring by an eye‑care professional is essential to detect and manage these events early.

Latanox should be avoided in individuals with known hypersensitivity to latanoprost or any component of the formulation. It is also contraindicated in eyes with active inflammation or infection, and caution is advised for patients with a history of uveitis, macular edema, or severe ocular surface disease.